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a b s t r a c t
A battery of toxicological studies was conducted in accordance with internationally accepted standards to
investigate the genotoxicity and repeated-dose oral toxicity of Fernblock®, a commercial aqueous extrac-
tion of the leaves of the tropical fern Polypodium leucotomos used for its oral and topical photoprotective
properties. No evidence of mutagenicity was observed in a bacterial reverse mutation test or in vitro
mammalian chromosomal aberration test nor was any genotoxic activity observed in an in vivo mouse
micronucleus test. Two repeated-dose oral toxicity studies were conducted in male and female Wistar
rats. In the ﬁrst study, no mortality or toxic effects were observed and no target organs were identiﬁed
at doses administered for 14 days by gavage up to the maximum dose of 5000 mg/kg bw/day. Based on
these results, a 90-day study was conducted at 0, 300, 600, and 1200 mg/kg bw/day. No mortality or
treatment-related adverse effects were observed and no target organs were identiﬁed. The NOAEL from
the 90-day study was determined to be 1200 mg/kg bw/day, the highest dose tested.
© 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Endemic to the Americas, Polypodium leucotomos (synonyms
Phlebodium aureum (L.) J. Sm., Polypodium aureum L.) is a fern
of the family Polypodiaceae, genus Phlebodium, with a tradi-
tional history of use in Central America, including as a poul-
tice for skin conditions (e.g., psoriasis and atopic dermatitis).Abbreviations: 2AA, 2-aminoanthracene; 9AA, 9-aminoacridine; ANOVA, analysis
of variance; BALT, bronchus associated lymphoid tissue; CoA, certiﬁcate of analysis;
DME, Dulbecco’s modiﬁed Eagle’s; DMSO, dimethyl sulfoxide; EMS, ethyl methane-
sulfonate; FOB, functional observation battery; KCl, potassium chloride; MPCE, mi-
cronucleated polychromatic erythrocytes; MMS, methyl-methanesulfonate; MSDS,
material safety data sheet; NOAEL, no observed adverse effect level; NPD, 4-Nitro-
1,2-phenylene-diamine; PCE, polychromatic erythrocytes; PLE, standardized aqueous
extract of the leaves of Polypodium leucotomos (Fernblock®); PUVA, psoralen-UVA;
SAZ, sodium azide; SOP, standard operating procedure; SPF, speciﬁc pathogen-free.
∗ Corresponding author.
E-mail addresses: tim@aibmr.com (T.S. Murbach), erzsebet.beres@toxicoop.hu
(E. Béres), adel.vertesi@toxicoop.hu (A. Vértesi), glavits.robert.dr@gmail.com
(R. Glávits), gabor.hirka@toxicoop.hu (G. Hirka), john@aibmr.com (J.R. Endres),
amy@aibmr.com (A.E. Clewell), ilona.pasics@toxicoop.hu (I.P. Szakonyiné).
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http://dx.doi.org/10.1016/j.fct.2015.11.008
0278-6915/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uGonzalez et al., 2011a) Over the past several decades there has
een a growing research interest in the mechanisms of action
nd clinical applications of extracts of P. leucotomos as anti-
nﬂammatory, immunomodulatory, antioxidant, and photoprotec-
ive agents.
P. leucotomos is rich in phenolic compounds, such as cinnamic,
hlorogenic, and ferulic acids, with known antioxidant properties.
Garcia et al., 2006; Gombau et al., 2006; Graf, 1992) The an-
ioxidant and other properties, such as anti-inﬂammatory effects,
mmunoregulation, tumor suppressing activity, and accelerated
isposal of UV-induced photoproducts, of the fern’s phenolic
ompounds contribute to its photoprotective effects. (Graf, 1992;
attra et al., 2009; Mulero et al., 2008; Janczyk et al., 2007;
iddelkamp-Hup et al., 2004a, 2004b) Because of the traditional
se history and the mechanisms of action elucidated using extracts
f P. leucotomos, its utility has been postulated and studied, both
lone and as an adjuvant, in a variety of skin conditions, including
rotection against the effects of acute sun exposure and photoag-
ng, (Gonzalez et al., 2010) and one recent review article con-
luded that oral use of P. leucotomos preparations could “providender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Aigniﬁcant advantages” as an adjuvant to sunscreens and other
ethods of physically blocking sun exposure. (El-Haj and Gold-
tein, 2015).
Fernblock®, a standardized aqueous extract of the leaves
f P. leucotomos (PLE) was developed to take advantage of
he fern’s photoprotective properties by providing a con-
istent phenolic content. Phenolic compounds identiﬁed in
ernblock® are 3,4-dihydroxybenzoic acid, 4-hydroxybenzoic
cid, 4-hydroxy-3-methoxy-benzoic acid (vanillic acid), 3,4-
ihydroxycinnamic acid (caffeic acid), 4-hydroxycinnamic acid
p-coumaric acid), 3-methyoxy-4-hydroxicinnamic acid (ferulic
cid), 4-hydroxycinnamoyl-quinic acid, and ﬁve isomers of chloro-
enic acid and account for approximately 1% (w/w) of the extract’s
ry weight. (Garcia et al., 2006) This PLE has been the subject
f multiple clinical and preclinical studies demonstrating its
echanistic potential and photoprotective utility (Garcia et al.,
006; Gombau et al., 2006; Zattra et al., 2009; Mulero et al.,
008; Janczyk et al., 2007; Middelkamp-Hup et al., 2004a, 2004b;
guilera et al., 2013; Ahmed et al., 2013; Alonso-Lebrero et al.,
003; Caccialanza et al., 2007, 2011; Capote et al., 2006; Gonzalez
t al., 2000; Gonzalez and Pathak, 1996; Gonzalez et al., 1997;
iddelkamp-Hup et al., 2007; Philips and Gonzalez, 2013; Philips
t al., 2003; Rayward et al., 1997; Reyes et al., 2006; Rodriguez-
anes et al., 2014, 2012) and is marketed throughout the world
or various skin-related applications. It has been demonstrated
o signiﬁcantly reduce skin damage from exposure to ultraviolet
adiation (Middelkamp-Hup et al., 2004a, 2004b; Aguilera et al.,
013; Gonzalez et al., 1997) and provide therapeutic beneﬁts
n the management of photodermatoses, (Tanew et al., 2012)
itiligo, (Middelkamp-Hup et al., 2007; Reyes et al., 2006) and
soriasis. (de las Heras et al., 1997) The ability of PLE to protect
gainst ultraviolet damage and/or sunburn and psoralen-induced
hototoxicity is of particular interest. Both topical application of
LE, according to FDA recommendations for sunscreen testing,
nd oral administration of 1080 mg PLE in divided doses to
ealthy subjects with type III and IV skin provided total protec-
ion against sunburn reaction following acute summer midday
un exposure at doses up to three minimal erythemal doses
MED). (Gonzalez et al., 1997) Furthermore, the treatments were
ighly statistically signiﬁcant compared to untreated control skin
atches of the topical group subjects. In the same study, both
opical and oral treatment increased the minimal phototoxic dose
MPD) in psoralen-sensitized subjects with the topical treat-
ent demonstrating statistical signiﬁcance. All treated groups
non-sensitized and psoralen-sensitized) showed histological ev-
dence of decreased photodamage. Similarly, two additional trials
emonstrated a photoprotective effect of oral PLE against acute
VA exposure in healthy subjects with normal type I and II skin
ith and without psoralen-UVA (PUVA) treatment, respectively.
Middelkamp-Hup et al., 2004a, 2004b) In both studies, treatment
ith two consecutive doses of PLE (7.5 mg/kg), approximately
2 h apart, prior to UVA exposure signiﬁcantly reduced both
ross and histopathological reactions to the exposure, and the
uthors concluded oral administration of the extract was effective
gainst PUVA-induced phototoxicity and UV-induced damage,
espectively.
PLE, marketed under the trade names Fernblock®, Fernplus®,
ernmed®, and Fernage® depending on the main application and
arget population, has been commercially available in Europe since
000, in both oral and topical preparations, and is currently mar-
eted in more than 26 countries, including the United States
here it has been available as a dietary supplement since 2006.
Choudhry et al., 2014) Biological mechanisms of broad utility,
avorable clinical outcomes, and the continued growth of inter-
st in natural products and natural alternatives to existing syn-
hetic products position PLE within an emerging trend to ex-lore systemic sun protection through increasing basal antiox-
dant threshold. (El-Haj and Goldstein, 2015; Gonzalez et al.,
011b).
To our knowledge, no formal toxicological studies on P. leuco-
omos extracts have been published, and because of the poten-
ial application of Fernblock® as an ingredient in food and/or di-
tary supplements it is important that its safety for these applica-
ions has been investigated and conﬁrmed. The small number of
on-serious, and lack of serious, adverse events reported in four-
een clinical trials involving P. leucotomos extracts (Middelkamp-
up et al., 2004a, 2004b; Aguilera et al., 2013; Ahmed et al., 2013;
accialanza et al., 2007, 2011; Gonzalez et al., 1997; Middelkamp-
up et al., 2007; Reyes et al., 2006; Jimenez et al., 1987; Moham-
ad, 1989; Padilla et al., 1974; Ramirez-Bosca et al., 2012; Solivel-
as and Martin, 2012) and its safe history of human use are en-
ouraging indicators of probable safety when consumed as cur-
ently suggested. Of the published trials, nine (Middelkamp-Hup
t al., 2004a, 2004b; Aguilera et al., 2013; Ahmed et al., 2013; Cac-
ialanza et al., 2007, 2011; Gonzalez et al., 1997; Middelkamp-Hup
t al., 2007; Reyes et al., 2006) used the speciﬁc PLE that is the
opic of this manuscript. Only three trials (one involving the PLE
Caccialanza et al., 2007) and two involving P. leucotomos rhizome
xtracts (Jimenez et al., 1987; Ramirez-Bosca et al., 2012)) reported
ccurrence of any adverse events (none were serious), and only an
dditional three (two involving the PLE (Caccialanza et al., 2011;
eyes et al., 2006) and one involving a P. leucotomos rhizome ex-
ract (Padilla et al., 1974)) speciﬁcally reported the absence of ad-
erse events. An earlier, unpublished toxicological safety assess-
ent, consisting of an Ames test and acute, 28-, and 90-day oral
oxicity studies in rodents, provided some insight suggesting a lack
f mutagenicity and oral toxicity of Fernblock®; however, these
tudies were less rigorous and used doses too low (200 mg/kg
w ﬁve days weekly in the repeated-dose studies) for relevance
o human consumption. Now, in order to more fully establish the
afety of Fernblock® for use in functional foods and beverages, a
omprehensive toxicological safety assessment according to inter-
ational standards and protocols was conducted and is herein re-
orted.
. Material and methods
.1. Chemicals
All chemical reagents, solvents, pharmaceuticals, and other
hemicals used in the studies were of analytical or pharma-
eutical grade. Agar bacteriological and nutrient broth num-
er 2 were purchased from Oxoid Ltd., (England); biotin,
-glucose-6-phosphate sodium, magnesium chloride (MgCl2),
-2-hydroxyethylpiperazine-N-2-ethane sulphonic acid (HEPES),
olchicine, trypsin ethylenediaminetetraacetic acid (EDTA) solution,
% methylcellulose, fetal bovine serum, methyl-methanesulfonate
MMS), 2-aminoanthracene (2AA), dimethyl sulfoxide (DMSO), Dul-
ecco’s modiﬁed Eagle’s (DME) medium, ethyl methanesulfonate
EMS), and cyclophosphamide monohydrate were purchased from
igma–Aldrich Co., (USA, Saint Louis, MO); l-histidine monohy-
rochloride monohydrate and monobasic sodium phosphate mono-
ydrate (NaH2PO4 × H20) were purchased from Fisher Scien-
iﬁc Co., (USA, Fair Lawn, NJ); potassium chloride (KCl), nutrient
gar, Giemsa stain, 4-Nitro-1,2-phenylene-diamine (NPD), sodium
zide (SAZ), and 9-aminoacridine (9AA) were purchased from
erck KGaA (Germany, Darmstadt); sodium chloride (NaCl), diba-
ic sodium phosphate dodecahydrate (Na2HPO4 × 12H2O), acetic
cid, methanol, and β-nicotinamide adenine dinucleotide phos-
hate (NADP) monosodium salt were purchased from Reanal Pri-
ate Ltd., (Hungary, Budapest); l-tryptophan was purchased from
crõs Organics (Belgium, Geel); rat liver S9 fraction (sourced from
330 T.S. Murbach et al. / Food and Chemical Toxicology 86 (2015) 328–341
Table 1
Typical compositional analysis of Fernblock®.
Analyte/Component Mean result (% (w/w) dry weight)
Cornstarch (carrier material) 87.2%
Moisture 4.5%
Polypodium derived saccharides 2.6%
Phenolic Compounds 1.0%
Quinic acid 0.7%
Salts 4.0%
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were met.
1 During the range ﬁnding test, molds and yeasts were observed growing on sev-
eral plates at the two highest concentrations (5000 and 2000 μg/plate); however,
the counts were identiﬁable and easily differentiated and did not disturb revertant
colony count evaluation in most cases. Nonetheless, in the initial and conﬁrma-
tory tests, three extra experimental plates (total of six parallel experiments) were
conducted at these concentrations to allow for an accurate evaluation procedure if
yeast and mold growth was observed on any plates.livers of phenobarbital/β-napththoﬂavone-induced rats) was pur-
chased from Moltox, Inc. (USA); methanol was purchased from
VWR International LLC (Belgium) methylcellulose was purchased
from Dow Chemical Company (Hungary); aqua puriﬁcata was pur-
chased from Parma Produkt Ltd. (Hungary); Isoﬂuran CP® was pur-
chased from CP-Pharma Handelsgesellschaft GmbH (Germany); and
Humapent 5 mg/mL eyedrops and Humaqua sterile water for injec-
tion were purchased from TEVA Pharmaceutical Works Private Ltd,
Co. (Hungary).
2.2. Test article
The test article was Fernblock®, also known as Fernplus®,
Fernmed®, and Fernage®, (Industrial Farmacéutica Cantabria (IFC),
Carretera Cazoña-Adarzo, s/n 39011, Santander, Spain), a commer-
cial aqueous extract of the leaves of P. leucotomos standardized
to contain 0.6–1.3% total phenolic compounds and 0.4–0.9% quinic
acid. The major component of Fernblock® is the cornstarch carrier
material and compositional analyses have identiﬁed the major P.
leucotomos derived constituents of Fernblock® to be salts, saccha-
rides, and phenolic compounds. A typical compositional analysis is
shown in Table 1 below.
Fernblock® was provided for use as the test article (batch num-
ber L-2623) along with speciﬁcations, certiﬁcate of analysis (CoA),
and material safety data sheet (MSDS), by the sponsor (IFC) of the
studies. Handling and disposal of the test article was in accordance
with instructions provided by the sponsor, and the identity of the
test article was veriﬁed analytically, based on information provided
in the CoA and MSDS, prior to beginning the studies.
2.3. Genotoxicity studies
The GLP studies reported below were conducted in compliance
with internationally accepted guidelines: OECD 471 (bacterial re-
verse mutation test), (Guideline for Testin, July 1997) OECD 473
(mammalian chromosomal aberration test), (Guideline for the Te,
July 1997) and OECD 474 (mouse micronucleus test) (Guideline
for the Te, 1997); ICH Guidance S2(R1) (bacterial reverse mutation
test) (International Conference, 2011); EC No. 440/2008 (all three
tests) (European Commission, 2008); and US EPA OPPTS 870.5100
(bacterial reverse mutation test), (EPA, 1998a) 870.5375 (mam-
malian chromosomal aberration test), (EPA, 1998b) and 870.5395
(mouse micronucleus test). (EPA, 1996) Care and use of animals in
the mouse micronucleus test was in compliance with laboratory
SOPs under the permission of the laboratory’s Institutional Animal
Care and Use Committee.
2.3.1. Bacterial reverse mutation test
The bacterial reverse mutation test was conducted to investi-
gate the mutagenic potential of Fernblock® according to the pro-
cedures established by Ames et al., (Ames et al., 1975) Maron
and Ames, (Maron and Ames, 1983) Kier et al., (Kier et al., 1986)
Venitt and Parry, (Venitt and Parry, 1984) Mortelmans and Zeiger,
(Mortelmans and Zeiger, 2000) and the test laboratory’s standardperating procedure (SOP) for preparations of frozen stock cul-
ure, raw data, and phenotype conﬁrmation. Bacterial tester strains
almonella typhimurium TA98, TA100, TA1535, and TA1537 and Es-
herichia coli WP2 uvrA were purchased from Moltox, Inc. (USA).
A preliminary solubility test was conducted by examining test
rticle mixtures of varying concentrations, and ultrapure water
ASTM Type 1, prepared in the laboratory by Direct-Q5 system,
illipore) was chosen as the vehicle for the bacterial reverse mu-
ation test. A preliminary range ﬁnding test (informatory toxicity
est) was then conducted in triplicate, with and without metabolic
ctivation, utilizing the plate incorporation method with appropri-
te positive and negative controls as described below. Six concen-
rations, 5000, 2000, 800, 320, 128, and 51.2 μg/plate, were se-
ected for the initial and conﬁrmatory tests based on the prelimi-
ary test results.
Test solutions were freshly prepared at the beginning of the
ain experiments by suspending varying amounts of Fernblock®
n 25 mL of ultrapure water to achieve concentrations of 100, 40,
6, 6.4, 2.56, and 1.024 mg/mL for administration of 50 μL of the
est solutions at the above determined concentrations per plate.
he corresponding strain speciﬁc positive controls (NPD, 9AA, SAZ,
nd MMS without S9 and 2AA with S9) were chosen according
o the review of Mortelmans and Zeiger (Mortelmans and Zeiger,
000) and in accordance with the OECD 471 Guideline. (Guideline
or Testin, July 1997) The negative (vehicle) control groups were ul-
rapure water for the test article and SAZ and MMS positive control
xperiments and DMSO for the NPD, 9AA, and 2AA positive control
xperiments.
The main testing procedure consisted of an initial mutation test
nd a conﬁrmatory mutation test. A standard plate incorporation
rocedure was used for the initial mutation test. Tester strains
ere exposed to the test article at each concentration and posi-
ive and negative (corresponding vehicle) controls both with and
ithout metabolic activation and incubated for 48 h at 37 °C. Each
xperimental condition was carried out in triplicate.1
The conﬁrmatory mutation test was conducted using a pre-
ncubation procedure. The negative (vehicle) control, test article
ose solutions, or positive controls, with and without S9-mix, were
ncubated for 20 min after which molten top agar was added and
he solutions were incubated for an additional 48 h on minimal
lucose agar plates. All experiments were conducted in triplicate. 1
Colony numbers were determined by manually counting; from
his mean values, standard deviations, and mutation rates were
alculated. A result was considered positive if:
 A dose-related increase in revertant colonies occurred; AND/OR
 A reproducible biologically relevant positive response for at
least one dose group occurred in at least one strain with or
without metabolic activation.
An increase was considered biologically relevant if:
 A reproducible increase in revertants at least twice as high as
the reversion rate of negative controls occurred in strain TA100.
 A reproducible increase in revertants at least three time higher
then the reversion rate of negative controls occurred in strains
TA98, TA1535, TA1537, or E. coli WPA uvrA.
A result was considered negative if neither of the above criteria
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t.3.2. In vitro mammalian chromosomal aberration test
Utilizing procedures described by Preston et al. (Preston et al.,
981) and Brusick, (Brusick and Hayes [ed.], 1989) the in vitro
ammalian chromosomal aberration test was conducted with and
ithout S9 metabolic activation in two independent experiments
o investigate the clastogenic potential of Fernblock®. The V79
ale Chinese hamster lung cell line used as the test system was
urchased from the European Collection of Cell Cultures (ECACC)
United Kingdom) and grown in supplemented DME medium.
DME medium was used as the solvent for the test article due
o its compatibility with test system and the availability of his-
orical control data. The stock solution was prepared by suspend-
ng the Fernblock® in DME medium to achieve a concentration of
0 mg/mL. Test solutions were freshly prepared at the beginning
f the experiment by diluting stock solution with DME medium to
chieve concentrations of 1250, 2500, and 5000 μg/mL.
The positive control for use without metabolic activation was
repared by dissolving EMS in DME medium to achieve concentra-
ions of 0.4, and 1.0 μg/mL, and the positive control for use with
etabolic activation was prepared by dissolving cyclophosphamide
n DME medium to achieve a concentration of 5.0 μg/mL. DME
edium served as the negative control.
A cytotoxicity assay was conducted as a pre-test for the pur-
ose of selecting concentrations for the main test. The cells were
reated with increasing concentrations of the test-article, with and
ithout S9 metabolic activation following the same procedures de-
cribed below for the main experiments except that cells were cov-
red with DME containing 10% fetal bovine serum and no growth
edium was added. Cell counts were performed following the
ampling times, and cytotoxicity was determined as percent sur-
ival in the treatment groups compared to the negative (solvent)
ontrol.
Two independent experiments were conducted in the main test.
79 cultures, 1–3 days old, were trypsinised, suspended in DME
edium, plated (5 × 105 cells/group), and incubated for 24 h.
he test-article was prepared as described above at concentrations
f 1250, 2500, and 5000 μg/mL. In Experiment A, V79 cultures
5 × 105 cells/group) were exposed to the negative control or each
est article concentration and incubated at 37 °C for a three-hour
eriod with and without S9 metabolic activation. Groups of cells
ere also exposed to the respective positive controls for use with
nd without S9 metabolic activation. Following the exposure pe-
iod, the cells were washed with DME medium containing 5% fetal
ovine serum and growth medium was added. Sampling was made
0 h (1.5 cell cycles) following the start of treatment. All individ-
al test-article and negative and positive control experiments were
arried out in duplicate and concurrent measures of cytotoxicity
ere also set up in the main tests and assessed as described for
he pre-test.
Experiment B was conducted as described for Experiment A ex-
ept that the exposure period without metabolic activation was
0 h, and sampling was made after 20 h for groups treated with-
ut metabolic activation and after 28 h (to cover the potential for
itotic delay) for groups treated both with and without metabolic
ctivation. Exposure and sampling times for experiments A and B
re summarized as follows:
 Experiment A: 3 h treatment with and without S9-mix/20 h
sampling time.
 Experiment B: 20 h treatment without S9-mix/20 and 28 h
sampling times.
 Experiment B: 3 h treatment with S9-mix/28 h sampling time.
The pH and osmolality of the negative control and treatment
olutions of all concentrations were measured in all three exper-
ments (pre-test, Experiment A, and Experiment B). In the main
xperiment (A & B), chromosomes were prepared for analysis byreatment with colchicine (0.2 μg/mL) for 2–3 h followed by har-
esting, swelling with 0.075 M KCl, and washing in ﬁxative for
pproximately 10 min before dropping onto slides, air-drying, and
taining with 5% Giemsa. Two hundred metaphase cells, containing
2 ± 2 centromeres, from each experimental group were evaluated
or structural aberrations (slides were coded and scored blind).
hromatid (gaps, deletions, and exchanges) and chromosome (gaps,
reaks, and exchanges) type aberrations were recorded separately.
olyploid and endoreduplicated cells were also scored. Nomencla-
ure and classiﬁcation of chromosomal aberrations were based on
ublications by ISCN (Hamden et al., 1985) and Savage. (Savage,
976).
The test article was considered non-clastogenic if:
 The number of metaphases with aberrations in all evaluated
dose groups was within the range of the laboratory’s historical
control data; AND/OR
 There were no statistically signiﬁcant increases in the number
of metaphases with aberrations compared to the negative con-
trol.
The test article was considered clastogenic if:
 An increased frequency, above the historical control range, of
metaphases with aberrations was observed at one or more test
concentrations; AND
 The increase was reproducible between replicate cultures and
between tests; AND
 The increase was statistically signiﬁcant compared to the nega-
tive control.
.3.3. In vivo mouse micronucleus test
The in vivo mouse micronucleus test was conducted to investi-
ate the genotoxic potential of Fernblock®. The experimental pro-
edures utilized have been described in the internationally ac-
epted guidelines (OECD, EC, and US EPA) cited above and by Sala-
one and Heddle (Salamone et al., 1983) and are summarized as
ollows:
The test article doses were prepared by suspending Fernblock®
n 1% methylcellulose to achieve concentrations of 50, 100, and
00 mg/mL in order to provide a constant dosing volume of
0 mL/kg bw. Doses were prepared daily by careful weight mea-
urement and administered within two hours due to lack of sta-
ility data for the preparations. The negative control groups re-
eived the same volume of the methylcellulose vehicle only. The
ositive control was prepared by dissolving cyclophosphamide in
terile water to achieve a concentration of 6.0 mg/mL for adminis-
ration of the standard dosing volume of 10 mL/kg bw.
Speciﬁc pathogen-free (SPF) male and female Crl:NMRI BR mice
Toxi-Coop, Budapest, Hungary) were utilized for the study and
oused in group (2 animal/cage in pretest and 5–7 animals/cage
n main test) type II polypropylene/polycarbonate cages with labo-
atory bedding at 22 ± 3 °C, 30–70% relative humidity and a 12-h
ight–dark cycle. The mice received ssniff® SM R/M-Z + H com-
lete diet for rats and mice and potable tap water ad libitum. A
re-experimental period of 6-days was provided to acclimatize the
nimals.
A non-GLP preliminary toxicity test was conducted to deter-
ine the appropriate high-dose for the main micronucleus test and
hether there were large gender differences in toxicity. A single
ose of Fernblock® was administered by gavage to two male and
emale Crl:NMRI BR mice at a concentration of 2000 mg/kg bw,
nd the animals were observed at regular intervals for three days
ollowing the treatment for signs of toxicity and mortality (bone
arrow smears were not prepared in the preliminary test).
In the main test, male Crl:NMRI BR mice were randomly di-
ided into groups of ﬁve (low- and mid-dose groups and posi-
ive control group), 10 (negative control group), and 12 (high-doses
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ggroup) animals. A single dose of Fernblock® was administered by
gavage at test concentrations of 0 (vehicle-control), 500, 1000, and
2000 mg/kg bw (the high-dose is the limit dose for mammalian
erythrocyte micronucleus tests and was selected based on the re-
sults of the preliminary acute toxicity test). The positive control,
cyclophosphamide 60 mg/kg bw, was administered by intraperi-
toneal injection. Two extra animals were included in the high-dose
group in order to maintain statistical power in case any animals
died before the scheduled sacriﬁces. In the case of no premature
deaths, bone marrow slides were not prepared from the extra ani-
mals.
All animals were observed immediately after dosing and at reg-
ular intervals until sacriﬁce (by cervical dislocation) for mortality,
visible signs of toxicity, or other reactions to treatment. Bone mar-
row smears were prepared in duplicate on standard microscope
slides from samples obtained from the femurs of ﬁve animals from
each dose group immediately following sacriﬁce according to the
following schedule: half the mice from the negative control and
high-dose groups and all mice from the low-dose, mid-dose, and
positive control groups were sacriﬁced 24 h post treatment, and
the remaining negative control and high-dose animals were sacri-
ﬁced at 48 h. Two thousand polychromatic erythrocytes (PCE) per
animal were scored for frequency of micronuclei with one slide
from each animal being scored blind (original animal numbers cov-
ered with a blinding code number). The proportion of PCE to ma-
ture erythrocytes per animal was determined by the number of
mature cells encountered while counting at least 200 PCE. Crite-
ria for a positive response were:
 Increased frequency of micronucleated PCE (MPCE) compared
to negative controls; AND
 The increases were dose related; AND
 The increases were statistically signiﬁcant; AND
 The increases exceeded historical control ranges for the labora-
tory.
2.4. 14- and 90-day repeated-dose oral toxicity studies in rats
The GLP 14-day and 90-day repeated-dose oral toxicity studies
in rats reported below were conducted in compliance with inter-
nationally accepted guidelines: OECD 407 (14-day study) (a) and
OECD 408 (90-day study), (b) and US FDA Redbook 2000, IV.C.3.a
(14-day study) (FDA, 2003a) and IV.C.4.a (90-day study). (FDA,
2003b) Care and use of study animals was in compliance with lab-
oratory SOPs under the permission of the laboratory’s Institutional
Animal Care and Use Committee, the National Research Council
Guide for Care and Use of Laboratory Animals, (NRC, 2011) and the
principles of the Hungarian Act 2011 CLVIII (modiﬁcation of Hun-
garian Act 1998 XXVIII) regulating animal protection.
The studies were conducted in order to evaluate the possi-
ble health hazards, including toxic effects and target organs, of
repeated oral exposure to Fernblock® in male and female rats
and to determine the respective no-observed-adverse-effect levels
(NOAEL). The 14-day study was also conducted as a dose range-
ﬁnding study for the 90-day study in order to provide data for the
selection of dose groups and identiﬁcation of target organs that
might require inclusion of extensive or extended organ speciﬁc de-
sign parameters.
The test article doses were prepared by suspending Fernblock®
in 0.5% methylcellulose to achieve concentrations of 50, 100, 200,
and 500 mg/mL (14-day study) and 30, 60, and 120 mg/mL (90-day
study) in order to provide a constant dosing volume of 10 mL/kg
bw. Doses were prepared daily by careful weight measurement and
administered within four hours due to lack of stability data for the
preparations. The negative control groups received the same vol-
ume of the methylcellulose vehicle only.Male and female SPF Crl:(WI)BR Wistar rats (Toxi-Coop, Bu-
apest, Hungary) were utilized in the studies, and the health status
f the rats was certiﬁed by the breeder. All animals were housed
ndividually at 22 ± 3 °C, 30–70% relative humidity, and a 12-h
ight–dark cycle in type III (14-day study) or type II (90-day study)
olypropylene/polycarbonate cages with certiﬁed laboratory wood
edding (Lignocel®, Germany). Cages and bedding were changed
wice a week during the 14-day study and once a week during the
0-day study. All animals received ssniff® SM R/M-Z + H complete
iet for rats and mice and potable tap water ad libitum. A pre-
xperimental period (7-days, 14-day study; 14-days, 90-day study)
as provided to acclimatize the animals.
At the start of the experimental periods, animals utilized in
he 14-day study were approximately ﬁve weeks old and weighed
72–199 g (males) and 124–148 g (females), and the 90-day study
nimals were approximately six to seven weeks and weighed
38–280 g (males) and 132–192 g (females). Fifty and 80 male
nd female SPF Wistar rats were stratiﬁed by weight and ran-
omly assigned to ﬁve groups of ﬁve and four groups of 10
ats/sex/group in the 14- and 90-day studies, respectively. The
est article, Fernblock®, was administered by gavage in doses of 0
vehicle-control), 500, 1000, 2000, and 5000 mg/kg bw/day (14-
ay study) and 0 (vehicle-control), 300, 600, and 1200 mg/kg
w/day (90-day study). Because the available literature on P. leu-
otomos and published, unpublished, and herein reported literature
nd data on Fernblock® does not suggest toxicity of the extract, the
igh dose for the 14-day study was set at 5000 mg/kg bw/day and
dditional doses were selected using a graduated declining dose
chedule to include four treatment groups in order to encompass
he broadest reasonable range of doses. Dose selection for the 90-
ay study was based on the absence of an observed maximum tol-
rated dose in the 14-day study. Because the high-dose in the 14-
ay study is far above limit doses typical of 90-day studies, we
alculated a high-dose based on information regarding high doses
sed in human clinical trials (Middelkamp-Hup et al., 2007; Reyes
t al., 2006) to provide a margin of exposure approximately 100-
old greater than highest human clinical exposures.
All animals in both studies were observed twice daily for mor-
ality. General cage-side observations for clinical signs were made
wice during the acclimation period and once daily after adminis-
ration of the test article during the 90-day study. Detailed clinical
bservations were conducted once daily during the 14-day study
nd once weekly during the 90-day study. A functional observa-
ion battery (FOB) was included in the 90-day study only and per-
ormed during the ﬁnal week to assess parameters such as gen-
ral physical condition and behavior, response to handling, sen-
ory reactions to various stimuli, grip strength, and motor activity.
Irwin, 1968) Measurements of body weight were conducted twice
uring the acclimation period, on the ﬁrst experimental day prior
o treatment, twice weekly during the course of the 14-day study
nd weeks 1–4 of the 90-day study, once a week during weeks 5–
3 of the 90-day study, and immediately prior to sacriﬁce in both
tudies. Food intake was determined and food eﬃciency calculated
nce weekly in both studies. Ophthalmological examination was
arried out on all animals of both studies prior to the experimental
eriod and at the end of the experimental period in all animals of
he 14-day study and control and high-dose group animals of the
0-day study.
After an overnight fast (approximately 16 h) following ﬁnal ad-
inistration of the test article, blood samples were collected from
he retro orbital venous plexus under Isoﬂuran CP® anesthesia af-
er which the animals were euthanized by exsanguination from
he abdominal aorta. Blood samples were analyzed for hemato-
ogic, blood coagulation, and clinical chemistry parameters and
ross pathological examinations and determinations of selected or-
an weights (absolute and relative) were conducted on all ani-
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cals. Full histopathological examinations were conducted on the
reserved organs and tissues of all animals of the control and
igh-dose groups and on a female animal of the 14-day study
000 mg/kg dose group that was found dead on day three of the
tudy. Histopathological examinations of organs in which gross le-
ions or other abnormalities were observed in animals of the lower
ose groups in both studies were also conducted.
.5. Statistical analyses
Statistical analyses were conducted using SPSS PC + software,
ersion 4 (SPSS, Inc., Chicago, IL). Per the adhered to guidelines,
he bacterial reverse mutation test results were interpreted based
n the criterion of biological relevance, and no statistical anal-
sis was performed. Fisher’s exact test and the Chi-square test
ere employed for analysis of the mammalian chromosomal aber-
ation test results. Analysis of the mouse micronucleus test was
onducted using Kruskal–Wallis non-parametric one-way analysis
f variance (ANOVA). For the 14- and 90-day oral toxicity studies
n rats, Bartlett’s homogeneity of variance test was used to assess
eterogeneity of variance between groups. A one-way ANOVA was
onducted where no signiﬁcant heterogeneity was detected fol-
owed by Duncan’s Multiple Range test to assess the signiﬁcance
f inter-group differences if a positive ANOVA result was obtained.
here signiﬁcant heterogeneity was detected by Bartlett’s test, the
olmogorov–Smirnov test was performed to examine normally dis-
ributed data, and Kruskal–Wallis non-parametric one-way ANOVA,
ollowed by the Mann–Whitney U-test for inter-group comparisons
f positive results, was used in the case of a non-normal distri-
ution. A P-value of <0.05 was considered statistically signiﬁcant,
nd statistically signiﬁcant results were reported at the p < 0.05
nd p < 0.01 levels.
. Results
.1. Genotoxicity studies
.1.1. Bacterial reverse mutation test
The resulting solutions of the preliminary solubility test
ielded concentrations of 5000, 2000, 800, 320, 128, 51.2, and
0.5 μg/tube and appeared clear to opalescent with increasing
oncentration. Although the highest concentration was not solu-
le, the homogenous suspension allowed for easy handling, and no
recipitate was observed on plates in subsequent experiments.
No cytotoxic or possible mutagenic effects of the test article
oncentrations or negative control were observed in the concen-
ration range ﬁnding (informatory toxicity) test. Revertant colony
umber increases were within the ranges of biological variability
f the strains under the applied conditions and historical control
ata.
In the initial and conﬁrmatory mutation tests, spontaneous re-
ertant colony numbers of the negative control plates in all ex-
eriments, both with and without S9 metabolic activation, were in
greement with the laboratory’s historical control data ranges. The
ositive controls in all experiments induced expected increases in
evertant colonies (at least a 3-fold increase) compared to nega-
ive controls. Neither growth inhibition nor dose-related or biolog-
cally relevant increases in the number of revertant colonies was
bserved with or without S9 on test article treated plates at any
oncentration in either the initial (Supplemental Table 1) or con-
rmatory (Supplemental Table 2) tests, and all results were within
he corresponding historical control data ranges. Several observed
poradic slight increases or decreases in revertant colony numbers
ompared to negative controls were far below the accepted criteria
or a positive response..1.2. In vitro mammalian chromosomal aberration test
A homogenous suspension of Fernblock® in DME medium
as obtained at concentrations up to 50 mg/mL in the pre-test.
he cytotoxicity assay was conducted at concentrations up to
000 μg/mL. After three hours of exposure to the test-article with
nd without metabolic activation, the relative survival at all con-
entrations compared to negative controls was 100–103% when
ampled 20 h after starting treatment. When treated for 20 h with-
ut metabolic activation, the relative survival at 5000 μg/mL com-
ared to negative control was 71 and 64%, respectively, at the 20
nd 28-h sampling times. The relative survival, at the 28 h sam-
ling time, of cells treated for three hours, at all concentrations
p to 5000 μg/mL, with metabolic activation was 95% of negative
ontrol survival. Additionally, the pH and osmolality of the nega-
ive control and all test article concentrations under all the tested
onditions remained unaffected and similar.
In the main experiment, the percentage of negative control
roup cells with structural aberrations without gap was ≤5%, and
iologically relevant increases in aberrations were observed in
ll positive control groups and were statistically signiﬁcant com-
ared to the negative controls. No statistically signiﬁcant differ-
nces were observed compared to negative controls in the num-
ers of chromatid or chromosome aberrations, at any test-article
oncentration, with or without metabolic activation, under any of
he exposure and sampling time combinations of Experiments A
Supplemental Tables 3 and 4) or B (Supplemental Tables 5–7). Ad-
itionally, there were no statistically signiﬁcant differences in the
ate of polyploidy and endoreduplicated metaphases under any of
he experimental conditions (data not shown). No dose–response
elationships were noted and all values remained within historical
ontrol data ranges. Results were not altered by inclusion or exclu-
ion of gap-type aberrations, and no signiﬁcant differences in pH
alue or osmolality were observed between the test article dose
roups and the negative control under any of the experimental
onditions.
.1.3. In vivo mouse micronucleus test
No mortality, signs of toxicity, or gender speciﬁc effects were
bserved in the preliminary toxicity test; therefore, the micronu-
leus test was conducted at doses of 0 (vehicle-control), 500, 1000,
nd 2000 mg/kg bw in males only.
No mortality, clinical signs of toxicity, or adverse reactions to
reatment were observed in any animals during the study. Be-
ause there was no mortality, bone marrow slides were not pre-
ared on the two extra animals included in the high-dose group.
o signiﬁcant differences were observed in frequency of MPCE be-
ween the three dose groups compared to the negative control
Supplemental Table 8) and all results were within the laboratory’s
istorical control range. The proportion of PCE to mature erythro-
ytes was similar among the three dose groups and the negative
ontrol (Supplemental Table 8). A large, statistically signiﬁcant in-
rease in MPCE frequency was observed in the positive control
roup compared to negative control.
.2. Oral toxicity studies
.2.1. 14-day repeated-dose oral toxicity study in rats
On study day 3, a single female animal of the 1000 mg/kg
w/day dose group was found dead. No abnormalities were ob-
erved in this animal during the acclimation period or on days 0,
, and 2 at the detailed clinical observations. Necropsy and sub-
equent histopathological examinations were conducted. Dark red
atches were observed on the lungs during the gross examina-
ion, and microscopic examination revealed corresponding conges-
ion and catarrhal inﬁltration in the lungs. No other mortalities oc-
urred during the 14-day treatment period of the study in any of
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sthe dose groups, and the remaining observations reported below
pertain to all animals excluding the dead female reported above.
There were no observations of abnormality in clinical signs, be-
havior, or physical condition of any animal during the daily de-
tailed clinical observations. No statistically signiﬁcant differences
in body weight, body weight gain, food consumption, or feed eﬃ-
ciency were observed in the test-article dose groups compared to
control groups throughout the study. No abnormalities were ob-
served on ophthalmologic examination of any animals before or at
the end of the treatment period.
A slight but statistically signiﬁcant decrease in platelet count
was observed for males of the 1000 mg/kg bw/day group, and
slight but statistically signiﬁcant elevations in mean corpuscular
hemoglobin for males of the 1000 and 5000 mg/kg bw/day groups
and prothrombin time (PT) and activated partial thromboplastin
time (APTT) for males of the 5000 mg/kg bw/day group were ob-
served compared to males of the control group (Supplemental Ta-
ble 9). No statistically signiﬁcant differences in hematological pa-
rameters were observed in females of any dose group compared
to controls. Sporadic statistically signiﬁcant differences in clinical
chemistry parameters observed between test article treated and
control animals of both sexes were within or marginal to histor-
ical control ranges (Supplemental Table 10).
Gross pathological examination was conducted and the follow-
ing observations were made (Supplemental Table 11): renal pale-
ness occurring in three, two, and three of ﬁve male animals of
the 1000, 2000, and 5000 mg/kg bw/day dose groups, respec-
tively; pyelectasia occurring in one of ﬁve males of both the con-
trol and 2000 mg/kg bw/day groups and one of ﬁve females of the
2000 mg/kg bw/day dose group; and hydrometra occurring in one,
one, and two of ﬁve females of the 500, 1000, and 2000 mg/kg
bw/day dose groups, respectively. No other gross pathological le-
sions were observed in any animals of the treatment or control
groups.
No statistically signiﬁcant differences in absolute organ weights
were observed between control groups and any of the test arti-
cle dose groups of male or female animals, and no statistically
signiﬁcant differences in relative organ weights were observed in
any of the male dose groups compared to controls. Slightly lower,
statistically signiﬁcant differences were observed in mean kidney
weight relative body to weight of the 500, 2000, and 5000 mg/kg
bw/day female dose groups compared to controls, and a slightly
higher, statistically signiﬁcant difference was observed in mean
spleen weight relative to body weight of the 2000 mg/kg bw/day
female dose group compared to controls (Supplemental Table 12).
On histopathological examination (Supplemental Table 13),
sporadic occurrence of alveolar emphysema and hyperplasiaTable 2
Summary of selecteda hematological ﬁndings in the 90-day repeated oral toxicity study.
Group (N = 10) (mg/kg bw/d) WBC (109/L) LYM (%)
Male
Control 9.69 ± 2.03 79.65 ± 3.47
300 8.18 ± 1.74 73.16 ± 8.27∗
600 8.36 ± 1.45 73.67 ± 7.88∗
1200 9.62 ± 1.99 77.34 ± 3.11
Historical Range 5.69–13.79 67.7–86.8
Female
Control 5.54 ± 1.19 80.22 ± 4.95
300 4.25 ± 1.19 77.05 ± 7.18
600 4.37 ± 0.76∗ 77.89 ± 4.57
1200 6.37 ± 2.24 78.63 ± 7.59
Historical Range 3.26–9.63 68.4–90.4
Abbreviations: WBC, white blood cell; LYM, lymphocyte; MONO, monocyte; PT prothromb
Data represent the mean values and the standard deviation.
∗P < 0.05 and ∗∗P < 0.01.
a Only parameters with statistically signiﬁcant ﬁndings are shown in table.f bronchus associated lymphoid tissue (BALT) were observed
ith similar frequency in control and high-dose group animals.
istopathologic examination of gross lesions observed in the lower
ose groups resulted in observation of a single-sided pyelecta-
ia, without degenerative, inﬂammatory, or ﬁbrotic lesions in the
000 mg/kg bw/day group female. No microscopic ﬁndings were
bserved in any of the other examined gross lesions.
.2.2. 90-day repeated-dose oral toxicity study in rats
No mortality was observed in the groups (0 (vehicle control),
00, 600, or 1200 mg/kg bw/day) during the 90-day treatment pe-
iod. The behavior and physical condition of all animals was con-
idered normal throughout the study. During daily cage-side and
eekly detailed clinical observations, various clinical signs were
oted in individual animals of all experimental groups as follows
Supplemental Table 14): piloerection occurring in one male con-
rol animal between days 71–76; a scab on the neck or nose occur-
ing in one female animal each of the control, 300 mg/kg bw/day
alopecia was also observed in this animal), and 600 mg/kg bw/day
roups, two females of the 1200 mg/kg bw/day group (alope-
ia was also observed in these animals), and one male of the
00 mg/kg bw/day group; brownish red fur around the right eye
as observed in one male of the 600 mg/kg bw/day group be-
ween days 11–89; and an increasing volume of swelling on the
eft hind limb was observed in one male of the 1200 mg/kg bw/day
roup between days 71–89 and was accompanied by piloerection,
ecreased activity, and paleness of the ears, eyes, and limb during
he last few days of the study.
One female animal of the control group was not suitable
or FOB examination due to extreme hyperactivity. Of the ex-
mined animals, the following FOB parameter differences were
oted: brownish red fur around the right eye of one 600 mg/kg
w/day group male (see clinical observations above and gross and
istopathology below); posterior position of the left hind limb
in the presence of a 2.5 cm reddish spherical swelling) of one
200 mg/kg bw/day group male (see clinical observations above
nd gross and histopathology below); and increased locomotor ac-
ivity (vigor movement, slightly sharp, rapid), touch escape re-
ponse (vigor, rapid escape), and positional struggle in one female
f the 300 mg/kg bw/day group. No differences in behavior, or sen-
ory reactions to various types of stimuli, grip strength, or locomo-
or activity were observed between controls and any other of the
reated animals.
A statistically signiﬁcant lower mean body weight gain was ob-
erved for the male 300 mg/kg bw/day group compared to con-
rols between days 0–4 (Supplemental Table 15), and statistically
igniﬁcant increased feed eﬃciency of the female 1200 mg/kgMONO (%) PT (sec) APTT (sec)
4.24 ± 0.78 22.43 ± 1.07 18.15 ± 2.21
5.05 ± 0.65∗ 23.56 ± 0.68∗ 20.40 ± 1.89
5.25 ± 0.88∗ 23.05 ± 0.90 19.54 ± 2.02
4.41 ± 0.99 22.72 ± 1.07 19.91 ± 2.13
1.4–6.3 19.4–25.8 14.3–23.1
2.84 ± 0.89 22.42 ± 1.39 19.01 ± 1.56
2.80 ± 0.80 22.59 ± 1.23 19.42 ± 1.14
2.94 ± 0.80 23.24 ± 0.70 21.56 ± 1.79∗∗
3.12 ± 0.90 21.80 ± 1.63 21.41 ± 2.35∗∗
0.8–4.5 19.3–25.4 12.8–21.9
in time; APTT, activated partial thromboplastin time.
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gw/day group compared to controls was observed on week 13
Supplemental Table 16). No other differences in body weight, body
eight gain, food consumption, or feed eﬃciency were observed
etween treated and control groups throughout the study.
On ophthalmologic examination prior to the start of the study,
thin grayish line was observed in the vitreous body of the left
ye of one female control and the right eye of one 300 mg/kg
w/day dose group female. This lesion was also observed in the
ontrol group female on ophthalmologic examination at the end
f the study. No other alterations were observed in the eyes of any
nimals before, or control and high-dose animals at the end of, the
tudy.
A slight but statistically signiﬁcant decrease in lymphocyte per-
entage and a slight but signiﬁcant increase in monocyte percent-
ge in the 300 and 600 mg/kg bw/day group males were observed
ith respect to controls. Also observed was a slight but statisti-
ally signiﬁcant increase in PT in the 300 mg/kg bw/day males. In
he females, a slight but statistically signiﬁcant decrease in white
lood cell count in the 600 mg/kg bw/day group and a slight but
tatistically signiﬁcant increase in APTT in the 600 and 1200 mg/kg
w/day groups were observed with respect to controls. These sta-
istically signiﬁcant differences observed in hematologic parame-
ers remained within historical control ranges of the laboratory
nd are summarized in Table 2. Various slight, but statistically sig-
iﬁcant, increases and decreases compared to controls were ob-
erved sporadically among the genders and dose groups, as shown
n Table 3, in clinical chemistry parameters: bilirubin, creatinine,
rea, cholesterol, bile acids, calcium, sodium, potassium, chloride,
lbumin, total protein, and albumin to globulin ratio.
Gross lesions observed at necropsy were (Supplemental Ta-
le 17): a vesicle-like, enlarged (6 cm dia), ﬂuid ﬁlled right kid-
ey and enlarged (3 cm dia) left kidney occurring in a single male
ontrol animal; smaller than normal testes and brownish red fur
round the right eye occurring, respectively, in different single in-
ividual male animals of the 600 mg/kg bw/day dose group; a
umor-like formation (red and soft, 5 cm dia) on the left hind limb,
ale liver, and enlarged spleen (7 cm long) occurring in one male
nimal of the 1200 mg/kg bw/day group (a pale liver was also ob-
erved in isolation of other lesions in another individual male an-
mal of the 1200 mg/kg bw/day group); hydrometra in two, three,
nd two of ten female animals of the control, 300, and 1200 mg/kg
w/day groups, respectively; a pale liver occurring in one female
nimal of the 300 mg/kg bw/day dose group; and an ovarian cyst
nd point-like hemorrhages in the thymus occurring, respectively,
n different single individual female animals of the 1200 mg/kg
w/day dose group.
Statistically signiﬁcant differences with respect to controls were
bserved in mean kidney weight relative to brain weight of the
ale 300 mg/kg bw/day dose group and mean testes weight
elative to body weight of the male 1200 mg/kg bw/day group
data not shown). No other differences with respect to controls
ere observed for absolute or relative organ weights in the male
ose groups. In the female dose groups, the following statisti-
ally signiﬁcant differences in absolute and relative organ weights
ith respect to controls were observed (Table 4): absolute brain
eight of all dose groups and brain relative to body weight of
he 1200 mg/kg bw/day group, absolute thyroid weight of the
00 mg/kg bw/day group and thyroid relative to body weight of all
ose groups, absolute and relative to body and brain weights of the
drenals of the 600 mg/kg bw/day group and adrenal weight rela-
ive to body weight of the 1200 mg/kg bw/day group, liver weight
elative to body weight of the 1200 mg/kg bw/day group, and body
eight relative to brain weight of the 1200 mg/kg bw/day group.
Upon histopathological examination, minimal or mild emphy-
ema was observed in the lungs of two of ten animals of each
ender of the control and high-dose groups, and acute hemor-
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Table 4
Summary of selecteda absolute and relative organ weights in female animals in the 90-day repeated oral toxicity study.
Group (N = 10)
(mg/kg bw/d)
Absolute organ weight (g) Organ weight relative to body weight (%) Organ & body weights relative to
brain weight (%)
Brain Adrenals Thyroidb Brain Liver Adrenals Thyroidb Body weight Adrenals
Control 2.05 ± 0.04 0.094 ± 0.013 0.026 ± 0.004 0.777 ± 0.077 2.682 ± 0.313 0.0358 ± 0.0067 0.0100 ± 0.0019 12981.8 ± 1331.84 4.60 ± 0.60
300 1.98 ± 0.11∗ 0.099 ± 0.011 0.021 ± 0.004∗ 0.757 ± 0.045 2.684 ± 0.175 0.0376 ± 0.0036 0.0081 ± 0.0017∗ 13257.9 ± 759.23 4.97 ± 0.34
600 1.99 ± 0.08∗ 0.074 ± 0.009∗∗ 0.022 ± 0.005 0.753 ± 0.055 2.515 ± 0.155 0.0278 ± 0.0030∗∗ 0.0082 ± 0.0018∗ 13346.7 ± 951.01 3.71 ± 0.41∗
1200 1.91 ± 0.13∗∗ 0.085 ± 0.012 0.022 ± 0.006 0.708 ± 0.056∗ 2.484 ± 0.126∗ 0.0314 ± 0.0043∗ 0.0081 ± 0.0019∗ 14202.5 ± 1135.98∗ 4.44 ± 0.60
Historical Range 1.69–2.11 0.062–0.119 0.016–0.072 0.582–0.912 2.255–3.144 0.0204–0.0469 0.006–0.027 10961.5–17175.1 3.02–6.75
Data represent the mean values and the standard deviation.
∗P < 0.05 and ∗∗P < 0.01.
a Only parameters with statistically signiﬁcant ﬁndings are shown in table.
b Thyroid weighed as thyroid and parathyroids together.
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Trhages were observed in the lungs of one of ten each of control
and high-dose females and two of ten high-dose males and in the
thymus of one of ten high-dose females. Hyperplasia of the BALT
was observed in three of ten control and one of ten high-dose
male animals and three of ten control and two of ten high-dose
female animals. Dilatation of the uterine horns occurred in two
of ten female animals of both the control and high-dose groups.
A vesicle-like kidney (one side) was observed in one male ani-
mal of the control group. Decreased intensity of spermatogenesis
in the testes and lack of mature spermatozoa in the epididymides
was observed in one male animal of the 600 mg/kg bw/day group.
One-sided conjunctivitis was observed in another individual male
animal of the 600 mg/kg bw/day group. A ﬁbrosarcoma accompa-
nied by extramedullary hematopoiesis in the liver and spleen was
observed in a single male animal of the 1200 mg/kg bw/day dose
group. An ovarian cyst was observed in one female animal of the
1200 mg/kg bw/day group. No morphological evidence of acute or
c
Table 5
Summary of histopathology ﬁndings in the 90-day repeated oral toxicity study.
Organs Observations Dose
Cont
Male
No microscopic ﬁndings 5/10
Eyes: Conjunctivitis (one side) 0/10
Epididymides: Lack of mature spermatoza 0/10
Kidneys: Cyst-like kidney (one side) 1/10c
Liver: Extramedullar hematopoiesis 0/10
Lungs: Alveolar emphysema 2/10
Acute pulmonary hemorrhage 0/10
Hyperplasia of BALT 3/10
Spleen Extramedullar hematopoiesis 0/10
Testes: Decreased intensity of spermatogenesis 0/10
Tumor Fibrosarcoma 0/10
Female
No microscopic ﬁndings 4/10
Liver: No lesions 10/10
Lungs: Alveolar emphysema 2/10
Acute pulmonary hemorrhage 1/10
Hyperplasia of BALT 3/10
Ovaries: Ovarian cyst (one side) 0/10
Thymus Acute thymic hemorrhage 0/10
Uterus: Dilatation of uterine horns 2/10g
Abbreviations:/, not examined; BALT, bronchus associated lymphoid tissue; N/A, not appli
Data represent the number of animals with observation per number of animals observed.
Organs without lesions in 10/10 control or high-dose animals not shown unless low- or m
a = Correlated ﬁnding across multiple examinations in animal #25; b = Correlated ﬁn
multiple examinations in animal #1; d = Correlated ﬁnding across multiple examinatio
#132; f = Correlated ﬁnding across multiple examinations in animal #136; g = Correlated
136.
a Low-dose group animal examined due to ﬁnding of hepatic paleness in the gross examubacute injury (e.g., degeneration, inﬂammation, necrosis) of the
ardiovascular, immune, hematopoietic, musculoskeletal, male or
emale reproductive, or central or peripheral nervous systems were
bserved, and the structure and cell morphology of the endocrine
lands was the same in control and high-dose group animals. The
bove histopathological observations are summarized in Table 5.
. Discussion and conclusions
While some toxicological investigations have been conducted
n pure isolated preparations of a few of the eight phenolic com-
ounds (considered to be the active antioxidant constituents) that
ave been identiﬁed in Fernblock®, (Garcia et al., 2006) to the
est of our knowledge, no other results of toxicological studies
ave been published on P. leucotomos or similar botanical species.
herefore, because of the extract’s potential to provide beneﬁ-
ial physiological effects when ingested by humans, in the currentgroup (mg/kg bw/d)
rol N = 10 300 N/A 600 N/A 1200 N = 10
N/A N/A 5/10
/ 1/1a 0/10
/ 1/1d 0/10
/ / 0/10
/ / 1/10b
/ / 2/10
/ / 2/10
/ / 1/10
/ / 1/10b
/ 1/1d 0/10
/ / 1/10b
N/A N/A 3/10
1/1a / 10/10
/ / 2/10
/ / 1/10
/ / 2/10
/ / 1/10e
/ / 1/10f
/ / 2/10g
cable (only animals with gross lesions were examined).
id-dose animals were also examined.
ding across multiple examinations in animal #32; c = Correlated ﬁnding across
ns in animal #28; e = Correlated ﬁnding across multiple examinations in animal
physiological ﬁnding across multiple examinations in animal #s 105, 110, 133, and
ination.
T.S. Murbach et al. / Food and Chemical Toxicology 86 (2015) 328–341 337
w
o
v
c
n
i
o
t
s
l
t
o
ﬁ
c
t
m
i
b
l
t
a
c
t
n
(
t
m
g
t
i
2
5
i
w
c
t
ﬁ
s
d
t
c
o
0
o
W
e
a
p
t
u
1
r
e
a
g
c
t
m
f
i
(
a
t
c
w
t
t
c
i
f
t
t
d
d
d
h
e
i
r
w
n
t
t
a
s
t
s
i
c
t
t
2
t
t
m
s
r
s
m
o
n
i
i
d
(
r
s
d
i
e
r
r
o
d
l
ﬁ
a
t
t
l
a
s
oork we investigated both the genotoxic potential and oral toxicity
f Fernblock® in order to ﬁll this gap.
The results of both the initial and conﬁrmatory bacterial re-
erse mutations tests on Fernblock® were considered unequivo-
ally negative; the slight sporadic increases in revertant colony
umbers compared to negative controls were far below genotox-
cologically relevant thresholds and considered reﬂective of the bi-
logical variability of the test system. Therefore, it was concluded
hat Fernblock® had no mutagenic activity in this test system.
Our results are consistent with the lack of mutagenicity ob-
erved by another group of investigators in an earlier unpub-
ished bacterial reverse mutation test on Fernblock®, at concen-
rations ranging from 195.312 to 6250 μg/plate, with and with-
ut metabolic activation, using the plate incorporation method in
ve S. typhimurium strains. Additionally, the phenolic compounds
hlorogenic and caffeic acids, in pure isolated forms, were not mu-
agenic by themselves, at high concentrations (up to 28 and 10
g/plate, respectively), in several bacterial reverse mutation tests
n S. typhimurium strains, (Fung et al., 1988; Stich et al., 1981)
ut did exhibit mutagenic activity in both an L5178Y TK+/- mouse
ymphoma assay (Fung et al., 1988) and a yeast gene conversion
est. (Stich et al., 1981) In the mouse lymphoma assay, chlorogenic
cid was positive with, but not without metabolic activation, and
affeic acid was positive without, but not with, metabolic activa-
ion (Fung et al., 1988); whereas, both were positive without, but
ot with, metabolic activation in the yeast gene conversion test.
Stich et al., 1981) Stich et al. also evaluated the mutagenic poten-
ial of quinic acid (a component of chlorogenic acid and surrogate
arker compound in Fernblock®), which was found to lack muta-
enic potential at very high concentrations (up to 203 mg/plate), in
he bacterial mutation test and was reported to be convertogenic
n the yeast gene conversion test only at a high concentration of
40 mg/mL (Stich et al., 1981).
For the in vitro chromosomal aberrations test on Fernblock®,
000 μg/mL was chosen as the high-dose for the main test exper-
ments based on the results of the preliminary cytotoxicity test in
hich Fernblock® was considered non-cytotoxic at all tested con-
entrations. In the main experiments A and B, the suitability of
he V79 cell line and the validity of the experiments were con-
rmed by the results for the negative and positive controls, re-
pectively. Fernblock® did not induce any signiﬁcant chromosomal
amage in V79 Chinese Hamster lung cells, and it was concluded
hat Fernblock® is not clastogenic in the applied test system.
In isolated pure form, phenolic constituents chlorogenic and
affeic acid were mildly (at least one aberration observed in ≤25%
f metaphases) clastogenic (at concentrations ranging from 0.1 to
.4 mg/mL) in chromosomal aberration assays in Chinese hamster
vary (CHO) cells without, (Stich et al., 1981; Hanham et al., 1983;
hitehead et al., 1983) but not with, metabolic activation. (Stich
t al., 1981; Whitehead et al., 1983) Quinic acid was also reported
s clastogenic at 50 mg/mL, but no further information was re-
orted. (Stich et al., 1981) In an in vitro sister chromatid exchange
est using human peripheral lymphocytes, caffeic acid, but not fer-
lic acid, exhibited mild clastogenic activity at a concentration of
00 μM. (Stagos et al., 2007) Although no statistical analysis was
eported in the chromosomal aberration assays conducted by Stich
t al., Whitehead et al., or Hanham et al., chlorogenic and caffeic
cid appear to have mild clastogenic potential. As with the muta-
enic potential observed in the yeast gene conversion test (and for
affeic acid only in the mouse lymphoma test), the clastogenic po-
ential appeared to be completely deactivated during mammalian
etabolism of the compounds.
Maistro et al., examined the genotoxic potential of caffeic and
erulic acids, at concentrations of 50, 500, and 1500 μM, in an
n vitro micronucleus assay using rat hepatoma tissue cells (HTC).
Maistro et al., 2011) Both compounds exhibited genotoxic activitys a dose-related increase in micronucleated cells that was statis-
ically signiﬁcant compared to controls at the two higher doses. A
omet assay, in which no genotoxic activity of either compound
as observed, was also conducted in HTCs at the same concen-
rations as part of this study. The lack of genotoxic activity in
he comet assay suggests that the effects seen in the micronu-
leus assay were due to clastogenicity. Pereira et al., conducted an
n vivo comet assay in rats administered 1 or 8 mg/kg bw caf-
eic acid by intraperitoneal injection. (Pereira et al., 2006) Only
he high-dose exhibited genotoxic activity in brain cells, and nei-
her dose was genotoxic in peripheral blood cells. Further, both
oses were protective against the genotoxic effects of ex vivo hy-
rogen peroxide treatment on the brain cells. Erdem et al., con-
ucted in vitro micronucleus and comet assays on vanillic acid in
uman lymphocytes at concentrations of 1 and 2 μg/mL (Erdem
t al., 2012) The higher concentration exhibited genotoxic activ-
ty in both assays; however, the criteria for judging a positive
esponse were not made clear. For example, no dose response
as observed (the frequency of micronucleated cells and the ge-
etic damage index in the micronucleus and comet assays, respec-
ively, at the lower concentration were less than observed for con-
rols). In additional experiments, both concentrations of vanillic
cid attenuated the genotoxic activity of the positive control sub-
tance, mitomycin C, when administered in combination. Moreover,
he authors of both studies reported that these compounds have
hown anti-genotoxic and anti-carcinogenic effects in other stud-
es.
With respect to the in vivo mouse micronucleus test of the
urrent work, Fernblock®, based on the results of the preliminary
oxicity test, was judged to lack acute toxicity in both sexes over
he appropriate test period and the high-dose was selected as
000 mg/kg bw. In the micronucleus test, because the response
o the positive control demonstrated an acceptable sensitivity of
he test and none of the criteria for a positive response were
et by any of the Fernblock® dose groups (all results being
imilar to negative control group results and within historical
anges) we conclude that Fernblock® is not genotoxic in this test
ystem.
Because the pure isolated compounds studied have shown
ixed results, the favorable results showing no genotoxic activity
f Fernblock® in our in vivo micronucleus assay, together with the
egative results observed in the bacterial reverse mutation and
n vitro mammalian chromosomal aberration tests, are important
n assessing the safety of this botanical extract that contains eight
ifferent interacting phenolic compounds in low concentrations
less than 1% combined of the total dry weight). These mixed
esults with respect to pure compounds, with some evidence
uggesting their deactivation during normal metabolism, do not
etract from the conclusion that, taken together, the in vitro and
n vivo genotoxicity test battery of the current work serves to
stablish a lack genotoxic potential of Fernblock®.
In considering the oral toxicity of Fernblock®, a 14-day
epeated-dose oral toxicity and range-ﬁnding study and 90-day
epeated-dose oral toxicity study were conducted in rats as part
f the current work. During the 14-day study (section 3.2.1), one
eath, in a low-mid-dose female, occurred on day 3. Due to its iso-
ated individual occurrence and because the gross and microscopic
ndings were consistent with gavage injury, the death was ruled
n individual ﬁnding without toxicological relevance and unrelated
o a systemic effect of the test-article. In the remaining animals,
here were no abnormal clinical observations, ophthalmologic
esions, or statistically signiﬁcant ﬁndings related to body weight
nd food consumption.
In the 90-day study (section 3.2.2), a small number of clinical
igns observed in two individual animals were associated with
ther exam ﬁndings as follows:
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t The histopathological ﬁnding of conjunctivitis in the right eye
of a single 600 mg/kg bw/day dose group male was associated
with the observed clinical sign and macroscopic observation of
brownish-red discoloration of the fur surrounding the eye in
the same animal.
 Histopathological ﬁndings of extramedullar hematopoiesis in
the spleen and liver and a ﬁbrosarcoma; gross ﬁndings of an
enlarged spleen, pale kidney, and tumor-like formation at the
left-hindlimb; and clinical signs of slightly decreased activity,
slight piloerection, swelling and paleness of the left hindlimb,
and paleness of the nose and ears were all correlated in a sin-
gle 1200 mg/kg bw/day male animal.
Due to the sporadic individual occurrences of the above ﬁnd-
ings and because they also occur spontaneously in untreated
experimental animals of this species, (Dixon et al., 1995; Greaves
et al., 2013; Johnson et al., 2013; Vandenberghe, 1990a, 1990b)
they were considered individual diseases without toxicological
relevance and unrelated to administration of the test article. The
small number of other isolated (without correlation to other exam
ﬁndings) clinical signs observed occurred with low and/or similar
incidence in controls and treated animals and are common obser-
vations in untreated experimental rats. (Krinke, 2000; Johnson and
Gad, 2007; Mecklenburg et al., 2013) Therefore, these were also
considered unrelated to administration of the test article.
The small number of differences observed on FOB parameters,
because of their individual occurrences, were considered indicative
of biological variation. The ophthalmologic lesion observed in
single control and 300 mg/kg bw/day group females is a sign
of very slight hyperplastic primary vitreous (a rare congenital
developmental anomaly of the eye also known as persistent fetal
vasculature) and was present in both animals prior to the start of
the study. For these reasons, the FOB and ophthalmologic obser-
vations were not considered toxicologically relevant or test-article
related. Due to their remaining within historical control ranges
of the laboratory (indicative of normal biological variation), low
magnitude, and transient occurrence at single time-points in single
male and female groups, respectively, the statistically signiﬁcant
observations related to body weight gain and feed eﬃciency were
also not considered to be of toxicological relevance or related to
administration of the test-article.
The statistically signiﬁcant alterations observed in hematologi-
cal and clinical chemistry parameters in the 90-day study animals
and remaining 14-day study animals were not considered to be
test article-related or toxicologically relevant because of their
sporadic occurrence without clear dose-relationships and/or low
magnitude (all remaining within or marginal to historical control
ranges of the laboratory) and the absence of related pathological
ﬁndings. Of the aforementioned ﬁndings, two clinical chemistry
parameters—creatinine and bile acids—with statistically signiﬁcant
decreases compared to controls, although remaining well within
historical control ranges, did appear to occur with a dose rela-
tionship in male animals of the 90-day study (see Table 3). With
respect to creatinine, increases rather than decreases are most
relevant clinically; however, low levels of creatinine are observed
in conditions of severe muscle wasting and may be falsely lowered
in conditions of the liver, infections, malnutrition, hemolytic ane-
mia, hyperthyroidism, and others. However, no correlating ﬁndings
in other clinical pathology parameters (e.g., bilirubin, erythrocyte
count), clinical signs, organ weights, or gross or histopathology
were observed. Likewise, elevations in total bile acids are the
most clinically relevant alteration of this parameter. Low levels of
bile acids (even to the undetectable level) are not unexpected in
the fasting state, are generally a reﬂection of a healthy state, and
are not generally considered abnormal although they may occur
in rare cases of transient decreases in bile ﬂow or ileal disease.owever, pathological changes in bile acids are expected to be ac-
ompanied by other related ﬁndings, which were not observed in
his study. Thus, the appearance of a potential dose-dependent ef-
ect in these two parameters, due to values remaining well within
istorical ranges and the lack of correlated ﬁndings (especially
ith respect to morphological and/or histopathological changes
n the kidneys or liver), is considered to be the result of chance
rrangement of normal biological variations within the group
andomization pattern. The statistically signiﬁcant differences
bserved in absolute (90-day females only) and/or relative organ
eights (14-day females and 90-day males and females) with
espect to controls were considered to represent normal biological
ariation and not to be toxicologically meaningful or related to
dministration of the test article due to their small degree (all
emaining within the historical control ranges of the laboratory)
nd lack of related ﬁndings in the histopathological examination
nd, in the male groups, their sporadic occurrence.
The remaining macro- and microscopic ﬁndings of the gross
nd histopathological examination were also not considered re-
ated to the test article. Acute alveolar emphysema (both studies)
nd pulmonary and thymic hemorrhages (90-day study) are
ommon consequences of hypoxia, dyspnea, and circulatory distur-
ances that can develop during exsanguination in the experience
f the laboratory, and thymic hemorrhages due to this cause
ave also been documented in the literature. (Johnson et al.,
013) Additionally, these lung lesions occur in control rats of
his strain, (Vandenberghe, 1990c) and thymic hemorrhages have
een documented as spontaneously occurring lesions in control
ats. (Dixon et al., 1995; Johnson et al., 2013) In the current
ork, due to their similar frequency of occurrence in control
nd high-dose animals and among genders, for the above rea-
ons, they were considered as resulting from the exsanguination
rocedure. The uterine dilatation (indicative of normal biologi-
al function associated with the proestrus phase of the female
strous cycle (Vidal et al., 2013)) (both studies) and pyelectasia
14-day study), observed in a few control and treated animals,
re species–speciﬁc alterations that occur in untreated animals of
his species. (Dixon et al., 1995; Johnson et al., 2013; Johnson and
ad, 2007; Vidal et al., 2013; Frazier and Seely, 2013; Hard et al.,
999) A vesicle-like kidney on the left and enlarged right kidney
bserved in a single male control animal (90-day study) were
onsidered spontaneous background lesions due to their common
ccurrence in rats and the congenital nature of the vesicle-like
idney. (Montgomery et al., 1990) The additional observations
n the 90-day study of smaller than normal testes associated
ith microscopic lesions in the testes (decreased intensity of
permatogenesis) and epididymides (lack of mature spermatozoa)
nd an ovarian cyst in individual male (600 mg/kg bw/day group)
nd female (1200 mg/kg bw/day group) animals, respectively,
re also common ﬁndings in untreated experimental rats, (Dixon
t al., 1995; Johnson et al., 2013; Johnson and Gad, 2007; Vidal
t al., 2013; Vandenberghe, 1990d) Finally, the microscopic lesion
f hyperplasia of BALT (both studies) is an immunomorphological
henomenon that occurs in response to antigenic stimulation and
an be pronounced. (Boorman et al., 1990; Haschek et al., 2009)
n the experience of the senior study pathologist (a contributing
uthor of the current work), when hyperplasia of the BALT occurs
n response to pathogenic respiratory infections, it is accompanied
y inﬂammatory lesions in the lungs, which were not present in
he current study; therefore, the observed hyperplasia of BALT, in
oth the control and high-dose groups (with greatest incidence in
he control animals), was considered due to stimulation by non-
iving antigens or commensal respiratory tract ﬂora. Hyperplasia
f the BALT is also observed in untreated (including germ-free)
xperimental rats. (Boorman et al., 1990; Haschek et al., 2009) For
he above reasons and because all observed lesions occurred as
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Eporadic lesions in individual animals they were not considered to
resent a toxicological concern or to be test-article related.
Based on the above interpretation of results, administration
f Fernblock®, by gavage, to male and female rats for 14 and 90
onsecutive days did not cause signs of toxicity. The NOAELs were
etermined to be 5000 and 1200 mg/kg bw/day, the highest doses
ested in each study respectively.
Our results are consistent with earlier internal work of the
anufacturer in demonstrating a lack of toxic effects. The unpub-
ished oral toxicity studies consisted of an acute study conducted
n Wistar rats and 28- and 90-day repeated-dose studies con-
ucted in NMRI mice. In the acute study, no mortality or toxic
ffects were reported during 14-days of observation following a
ingle dose of 2000 mg/kg bw of Fernblock®; however, speciﬁc ob-
ervations made were not reported. In the 28- and 90-day studies,
roups of male and female mice were administered 200 mg/kg bw
ernblock® or vehicle control ﬁve days per week (with no dosing
n Saturdays and Sundays). No toxicologically relevant ﬁndings
ere reported; however, each study failed to report results of
arious different observations and analyses, and no statistical
nalyses were conducted.
While the reported results of these studies appear to be gen-
rally consistent with the results observed in our 14- and 90-day
tudies, the doses used were too low for extrapolation to the safety
f typical levels of human consumption. In our current work, full
ompliance with international protocols provides a robust safety
valuation of Fernblock® due to inclusion of hematological and
linical chemistry evaluations, full gross and histopathological
xaminations, evaluation of relative and absolute organ weights,
nd inclusion of appropriate statistical analyses. Additionally,
he dose selection and use of multiple graduated declining dose
roups has provided results that are relevant and meaningful in
he evaluation of safe human intake levels.
The low occurrence of adverse events observed in clinical trials
nvolving P. leucotomos and the history of consumption of P. leuco-
omos as a commercial extract for more than 30 years, as well as a
ong history of traditional use, without safety concerns support our
onclusion that this currrent work, and especially the NOAEL of
he 90-day study, provides meaningful evidence in consideration
f the safety of consumption of Fernblock® by humans. Because
he NOAEL in 90-day study was the highest dose tested, future
tudies at higher doses may be considered in order to further
haracterize the safety of this ingredient for human consumption.
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